- Home
- ASND vs EXEL Comparison
ASND vs EXEL Comparison
Compare ASND & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASND | EXEL |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 11.1B |
| IPO Year | 2015 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ASND | EXEL |
|---|---|---|
| Price | $212.73 | $44.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 24 |
| Target Price | ★ $256.27 | $44.73 |
| AVG Volume (30 Days) | 571.7K | ★ 2.8M |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | N/A | ★ 2.38 |
| Revenue | $758,592,045.00 | ★ $2,288,218,000.00 |
| Revenue This Year | $104.98 | $9.14 |
| Revenue Next Year | $79.91 | $12.51 |
| P/E Ratio | ★ N/A | $18.59 |
| Revenue Growth | ★ 97.46 | 9.93 |
| 52 Week Low | $118.03 | $31.90 |
| 52 Week High | $223.19 | $49.62 |
Technical Indicators
Market Signals| Indicator | ASND | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 57.24 | 65.52 |
| Support Level | $203.02 | $41.65 |
| Resistance Level | $218.50 | $42.99 |
| Average True Range (ATR) | 10.28 | 1.25 |
| MACD | 0.40 | 0.18 |
| Stochastic Oscillator | 69.31 | 88.98 |
Price Performance
Historical ComparisonAbout ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.